Taletrectinib Demonstrates Durable Long-Term Efficacy in Both TKI-naïve and Crizotinib-pretreated Patients with Advanced ROS1-positive NSCLC By Ogkologos - May 7, 2026 82 0 Facebook Twitter Google+ Pinterest WhatsApp Updated efficacy and safety results from the TRUST-I study Source RELATED ARTICLESMORE FROM AUTHOR FDA Approves Two Separate Indications for fam-Trastuzumab Deruxtecan-nxki in HER2-Positive Early-Stage Breast Cancer ESMO Calls for Further EU Measures Enhancing Europe’s Clinical Trial Regulatory Ecosystem Following Meeting of Health Ministers on 16 June 2026 ESMO Responds to Public Consultation on EU4Health Work Programme for 2027 and Highlights the Importance of Continuing Robust EU Support for Europe’s Beating Cancer... MOST POPULAR Therapy Rottweiler, known as Dogtor Loki, Is Delivering ‘Hero Healing Kits’... April 16, 2020 Dame Deborah James’ incredible legacy: The Bowelbabe Fund announces first funded... April 5, 2023 VA Study Finds No Disparities in Prostate Cancer Deaths with Equal... February 18, 2020 Cancer in My Community: Addressing Health Disparities in Brazil July 18, 2023 Load more HOT NEWS Working Mom with Stage II Breast Cancer Receives Custom Wig Made... Adding Lenvatinib to Pembrolizumab Does Not Provide Additional Benefit in Patients... Avelumab Ineffective in Patients with MSS Endometrial Cancer Carrying TP53 Mutation 18-Year-Old Jaguar at Akron Zoo Diagnosed with Breast Cancer
